The Toronto Prehospital Hypertonic Resuscitation Head Injury and Multi Organ Dysfunction Trial (TOPHR HIT) (TOPHR HIT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01642524|
Recruitment Status : Completed
First Posted : July 17, 2012
Last Update Posted : July 17, 2012
|Condition or disease||Intervention/treatment||Phase|
|Traumatic Brain Injury||Biological: hypertonic saline mixed Dextran Biological: Saline solution||Phase 3|
The primary objective of this study is to report feasibility in accordance with the methodology described by Lancaster and Dodds, specifically addressing:
- baseline survival rates for the treatment and control group to aid in the design of a definitive multicentre trial.
- randomization compliance rate.
- ease of protocol implementation in the out-of-hospital setting.
- adverse rate of Hypertonic Saline Dextran (HSD) infusion.
The secondary objectives include measuring the effect of HSD in modulating the immuno-inflammatory response to severe head injury and its effect on modulating the release of neuro-biomarkers into serum; evaluating the role of serum neuro-biomarkers in predicting patient outcome and clinical response to HSD intervention; evaluating effects of HSD on brain atrophy post-injury and neurocognitive and neuropsychological outcomes.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||114 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Double (Participant, Care Provider)|
|Official Title:||The Toronto Prehospital Hypertonic Resuscitation-Head Injury and Multi Organ Dysfunction Trial|
|Study Start Date :||April 2004|
|Actual Primary Completion Date :||January 2006|
|Actual Study Completion Date :||July 2011|
Experimental: hypertonic saline mixed Dextran
hypertonic saline mixed Dextran
Biological: hypertonic saline mixed Dextran
single dose administered intravenously
Placebo Comparator: Placebo controlled
Biological: Saline solution
placebo - saline solution
- 30 day survival [ Time Frame: 30 days after discharge ]
- Survival [ Time Frame: 48 hrs after admission ]•Survival: 48 hours after admission; Hospital discharge
- Functional neurological outcomes at 4 months [ Time Frame: 4 Months ]
- Neuropsychological testing at 4 months [ Time Frame: 4 months ]
- Neuropsychological testing at 1 year [ Time Frame: 1 year ]
- Physiologic parameters indicative of organ dysfunction [ Time Frame: 4 months ]
- Structural parameters indicative of brain injury or dysfunction at 4 months [ Time Frame: 4 months ]
- Serum inflammatory markers measured on arrival, 12, 24, 48 hours later [ Time Frame: 12, 24, 48 hours later ]